Experience in the use of dalbavancin in diabetic foot infection.

Autor: Navarro-Jiménez G; Servicio de Medicina Interna, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España. Electronic address: gema.nvj@gmail.com., Fuentes-Santos C; Escuela Internacional de Doctorado, Universidad Rey Juan Carlos, Móstoles, Madrid, España., Moreno-Núñez L; Sección de Enfermedades Infecciosas, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España., Alfayate-García J; Servicio de Cirugía Vascular, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España., Campelo-Gutierrez C; Servicio de Microbiología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España., Sanz-Márquez S; Servicio de Farmacia, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España., Pérez-Fernández E; Unidad de Investigación, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España., Velasco-Arribas M; Sección de Enfermedades Infecciosas, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España., Hervás-Gómez R; Sección de Enfermedades Infecciosas, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España., Martín-Segarra O; Sección de Enfermedades Infecciosas, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España., Losa-García JE; Sección de Enfermedades Infecciosas, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España.
Jazyk: English; Spanish; Castilian
Zdroj: Enfermedades infecciosas y microbiologia clinica (English ed.) [Enferm Infecc Microbiol Clin (Engl Ed)] 2021 Jan 12. Date of Electronic Publication: 2021 Jan 12.
DOI: 10.1016/j.eimc.2020.11.013
Abstrakt: Objective: To describe the clinical experience with dalbavancin in the treatment of diabetic foot infection in a multidisciplinary unit of a second level hospital.
Methods: A retrospective, descriptive study was made with all patients with diabetic foot infection treated with dalbavancin in the Diabetic Foot Unit of Hospital Universitario Fundación Alcorcón, covering the period from September 2016 to December 2019. Demographic parameters and comorbidities, characteristics of the infection and treatment with dalbavancin were recorded. The cure rate was estimated at 90 days after finishing the treatment.
Results: A total of 23 patients with diabetic foot infection (osteomyelitis) started treatment with dalbavancin, 19 were men and the mean age was 65 years. The microorganisms most frequently isolated for the indication of treatment with dalbavancin were Staphylococcus aureus (11) and Corynebacterium striatum (7). Dalbavancin was used as a second choice therapy in 22 cases, in 11 due to toxicity from other antibiotics. The median duration of treatment was 5 (4-7) weeks; the most frequent dose of dalbavancin (8 patients) was 1000mg followed by 500mg weekly for 5 weeks. 3 patients presented mild side effects (nausea and gastrointestinal discomfort). At 90 days after completion of dalbavancin therapy, 87% (20) of the patients were cured (95% CI: 65.2%-94.52%).
Conclusion: Patients with osteomyelitis due to gram-positive microorganisms who received as part of the multidisciplinary antibiotic treatment with dalbavancin, had a high rate of cure with adequate tolerance and few side effects. Dalbavancin offers a safe alternative in treating deep diabetic foot infection.
(Copyright © 2020 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: